ST Xiangxue announced that its subsidiary, Xiangxue Life Science Technology Co., Ltd. received two “Drug Clinical Trial Approval Notices” issued by the State Drug Administration, and that the application for clinical registration of the new XLS-103 injection drug from Xiangxue Life Science obtained clinical trial permits.

ST Xiangxue announced that its subsidiary, Xiangxue Life Science Technology Co., Ltd. received two “Drug Clinical Trial Approval Notices” issued by the State Drug Administration, and that the application for clinical registration of the new XLS-103 injection drug from Xiangxue Life Science obtained clinical trial permits.